Wearables are entering psychedelic research.
What’s happening: Smart ring maker Oura joined an INVI MindHealth research project, contributing biometric data to study veterans undergoing psychedelic therapies, neuromodulation, and other emerging treatments.
Full picture. Combining sleep, HRV, temperature, activity, and recovery metrics with EEGs, behavioral assessments, and clinical outcomes, the ARPA-H-funded initiative aims to build a longitudinal view of mental health.
Exploring the brain, Oura also announced a joint study with UK-based neuroscience company Cambridge Cognition in May, adding cognitive assessment tools as an opt-in Oura Labs feature.
Next layer. As psychedelics move closer to mainstream medicine, new models for mental health care delivery, diagnostics, and patient monitoring are emerging. Meru Health blends digital psychiatry with biomarker tracking and Radial integrates neuromodulation, wearables, and AI — while WHOOP lets members track ketamine, psilocybin, and LSD experiences.
Takeaway: Precision mental healthcare is becoming a reality. Companies that integrate biomarkers, clinical context, and longitudinal data are building the infrastructure connecting treatments, clinicians, and patients.
